Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KDM5C | P41229 | 3/20 | 0.40 |
| ▸ | KDM6B | O15054 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755487 | 0.87 | KMT2A (0.39) | MAPK1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL7256359 | 0.83 | LMNA (0.58) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL8925914 | 0.83 | SLC22A6 (0.58) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL21422304 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL21318205 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL21422305 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL21318214 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL21422313 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL25928800 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 | |
| SCHEMBL14519724 | 0.81 | TSHR (0.60) | LMNAOR51E2SLC22A6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882252-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025024714-A2 | BONE-TARGETED CANONICAL NOTCH INHIBITOR | BIOVENTURES, LLC (US) | 2025-01-30 | — | — | WO | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | MITOPOWER LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | MITOPOWER LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009504-A1 | Antifungal agents | SCYNEXIS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| EP-0827507-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-03-11 | — | — | EP | disclosed |
| WO-1996031527-A1 | PROTEASE INHIBITING SUCCINIC ACID DERIVATIVES | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1996-10-10 | — | — | WO | disclosed |
| EP-0704424-A1 | 3-alkoxypropionic ester derivative, olefin polymerization catalyst, and process for preparation of polyolefin | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279053-A1 | GLP-1 RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | EGLN1 1009/4885LMNA 2578/4885ALKBH5 4798/4885 |
| US-20080009504-A1 | Antifungal agents | DPM1, MAN2B1, MAN2A1 | EGLN1 998/4885LMNA 3407/4885ALKBH5 3031/4885 |
| US-20230255995-A1 | Nicotinyl Riboside Compounds and Their Uses | NADK, NNT, NAMPT | EGLN1 2190/4885LMNA 800/4885ALKBH5 4271/4885 |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | EGLN1 1401/4885LMNA 877/4885ALKBH5 2169/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | EGLN1 495/4885LMNA 3843/4885ALKBH5 2444/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | EGLN1 113/4885LMNA 868/4885ALKBH5 680/4885 |
| US-11833167-B2 | Nicotinyl riboside compounds and their uses | NADK, NNT, NAMPT | EGLN1 2213/4885LMNA 608/4885ALKBH5 4165/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | EGLN1 4753/4885LMNA 2413/4885ALKBH5 1755/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | EGLN1 4188/4885LMNA 2495/4885ALKBH5 4050/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | EGLN1 4350/4885LMNA 2744/4885ALKBH5 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.